Researchers at the University of Michigan presented preclinical data for a three‑part antibody‑oligonucleotide conjugate that ferries antisense oligonucleotides into neurons after crossing the blood‑brain barrier via transferrin receptor engagement. The construct couples a BBB shuttle with neuron‑targeting components to direct ASOs to neuronal populations, addressing post‑entry biodistribution challenges for CNS oligo therapies. Yunxuan Xie and the Tessier lab showed in vivo data at Antibody Engineering and Therapeutics USA indicating improved neuronal uptake and gene knockdown compared with unconjugated ASOs, which are prone to clearance in liver and kidneys. The multitargeting design aims to reduce the need for invasive intrathecal delivery. If reproducible and safe in larger models, this delivery modality could broaden the scope of ASO therapies for neurodegenerative and genetic CNS disorders by improving cell‑type specificity and distribution.